Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ATAI Life Sciences (ATAI)
NASDAQ:ATAI
Holding ATAI?
Track your performance easily
ATAI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.03 - $2.85
Previous Close$1.46
Volume2.46M
Average Volume (3M)789.29K
Market Cap
$244.99M
Enterprise Value$242.37M
Total Cash (Recent Filing)$19.33M
Total Debt (Recent Filing)$16.07M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Mar 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding167,798,955
10 Day Avg. Volume1,836,234
30 Day Avg. Volume789,294
Standard Deviation0.17
R-Squared0.05
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)1.46
Price to Sales (P/S)701.38
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue641.19
Enterprise Value/Gross Profit771.88
Enterprise Value/Ebitda-9.82
Forecast
1Y Price Target
$10.67Price Target Upside690.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
ATAI Life Sciences News
PremiumCompany Announcements
Atai Life Sciences Advances Psychedelic Treatments in Q3 2024
PremiumCompany Announcements
ATAI Life Sciences Reports Q3 Results and New Trials
PremiumPre-Earnings
Is ATAI a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Financial StabilityATAI continues to expect a cash runway into 2026E, and operating expense estimates are generally consistent with this.
PartnershipThe partnered programs with Beckley PsyTech continue to advance with complete enrollment for the P2b in major depressive disorder expected.
PipelineATAI is developing a pipeline of compounds focused on mental health conditions, where the unmet need remains very high.
Bears Say
Clinical DevelopmentEnrollment for RL-007 is taking longer than expected, which may delay the top-line data release.
Lead Program RisksRisks include clinical development risk tied to lead programs GRX-917, RL-007, and VLS-01, among others.
Regulatory RisksRisks include, but are not limited to: clinical development risk, competitor risk, government regulatory risk, capital market and dilution risk, commercialization risk, reimbursement risk, pricing risk, business development risk, risk from COVID-19, and disruptions to clinical trials owing to the war in Eastern Europe.
---
Ownership Overview
33.60% Insiders
0.62% Mutual Funds
0.66% Other Institutional Investors
63.87% Public Companies and Individual Investors
ATAI FAQ
What was ATAI Life Sciences’s price range in the past 12 months?
ATAI Life Sciences lowest stock price was $1.02 and its highest was $2.85 in the past 12 months.
What is ATAI Life Sciences’s market cap?
Currently, no data Available
When is ATAI Life Sciences’s upcoming earnings report date?
ATAI Life Sciences’s upcoming earnings report date is Mar 27, 2025 which is in 133 days.
How were ATAI Life Sciences’s earnings last quarter?
ATAI Life Sciences released its earnings results on Nov 12, 2024. The company reported -$0.16 earnings per share for the quarter, the consensus estimate of -$0.16 by $0.
Is ATAI Life Sciences overvalued?
According to Wall Street analysts ATAI Life Sciences’s price is currently Undervalued.
Does ATAI Life Sciences pay dividends?
ATAI Life Sciences does not currently pay dividends.
What is ATAI Life Sciences’s EPS estimate?
ATAI Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ATAI Life Sciences have?
ATAI Life Sciences has 167,798,950 shares outstanding.
What happened to ATAI Life Sciences’s price movement after its last earnings report?
ATAI Life Sciences reported an EPS of -$0.16 in its last earnings report, expectations of -$0.16. Following the earnings report the stock price went down -7.595%.
Which hedge fund is a major shareholder of ATAI Life Sciences?
Among the largest hedge funds holding ATAI Life Sciences’s share is Lumina Fund Management Llc. It holds ATAI Life Sciences’s shares valued at N/A.
---
ATAI Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.67 (690.37% Upside)
$10.67 (690.37% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 17.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 2.3%
Last 30 Days ▼ 2.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
24.78%
12-Months-Change
Fundamentals
Return on Equity
-30.53%
Trailing 12-Months
Asset Growth
-14.91%
Trailing 12-Months
Company Description
ATAI Life Sciences
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.
---
ATAI Stock 12 Month Forecast
Average Price Target
$10.67
▲(690.37% Upside)
Technical Analysis
Best Analysts Covering ATAI
1 Year
1 Year Success Rate
5/23 ratings generated profit
1 Year Average Return
-29.27%
reiterated a buy rating 2 months ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 21.74% of your transactions generating a profit, with an average return of -29.27% per trade.
---